The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: A double-blind, randomized, placebo-controlled clinical trial

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 60, Issue 5, 2005, Pages 648-653

  Frisoli Jr , Alberto ^a,c   Chaves, Paulo H M ^b   Pinheiro, Marcelo Medeiros ^a   Szejnfeld, Vera Lucia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; NANDROLONE DECANOATE; PLACEBO;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR; FEMUR NECK; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; LEAN BODY WEIGHT; LUMBAR SPINE; MAJOR CLINICAL STUDY; MUSCLE MASS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

EID: 20744460348     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/60.5.648     Document Type: Article

References (39)

1. United Nations Population Division. World Population Prospects: The 1998 revision. New York, NY: Population Reference Bureau; 1998.
2. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: How many women have osteoporosis? J Bone Miner Res. 1992;7:1005-1010.
3. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72-75.
4. Marshal D, Schnell O, Wedel H, et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
5. nd edition. Philadelphia, PA: Lippincott-Raven Publishers; 1995;225-247.
6. Haden ST, Glowacki J, Hurwitz S, et al. Effects of age on serum dehydroepiandrosterone sulfate. IGF-1, and IL-6, levels in women. Calcif Tissue Int. 2000;66:414-418.
7. Ravn P, Overgaard K, Spencer EM, Christiansen C. Insulin-like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol. 1995;132:313-319.
8. Kasperk CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989; 124:1576-1578.
9. Masuyama A, Ouchi Y, Sato F, et al. Characteristics of steroid of hormone receptors in cultured MC3T3-E1 osteoblastic cells and effect of steroid hormones on cell proliferation. Calcif Tissue Int. 1992; 51:376-381.
10. Nakano Y, Morimoto I, Ishida O, et al. The receptor, metabolism and effects of androgen in osteoblastic MC3T3-E1 cells. J Bone Miner Res. 1994;26:245-259.
11. Kasperk CH, Wakley GK, Hier T, et al. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res. 1997;12:464-471.
12. Garnero P, Sornay-Reundu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000; 15:1526-1536.
13. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res. 2003;18:393-405.
14. Saaf M, Hilding A, Thoren M, Troell S, Hall K. Growth hormone treatment of osteoporotic postmenopausal women-a one-year placebo-controlled study. Eur J Endocrinol. 1999;140:390-399.
15. Villareal DT, Hollooszy JO, Kohrt WM. Effect of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol. (Oxf) 2000;53:561-568.
16. Boonen S, Broos P, Dequeker J, et al. The prevention or treatment of age related osteoporosis in the elderly by systemic recombinant growth factor therapy (rhIGF-I or rhTGFbeta): a perspective. J Intern Med. 1997;242:285-290.
17. Jassen JL, Burger H, Stolk RP, et al. Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol. 1998;138:627-632.
18. Ohlsson C, Jasson JO, Isaksson O, et al. Effects of growth hormone and insulin like growth factor-I on body growth and adult bone metabolism. Curr Opin Rheum. 2000;12:346-348.
19. Gennari C, Agnusdei D, Gonnelli S, et al. Effeti ossei della terapia com nandrolone decanoato nellaosteoporosi post menopausale. Minerva Endocrinol. 1989;14:69-74.
20. Need AG, Chatterton BE, Walker CJ, et al. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas. 1986;8:275-280.
21. Need AG, Morris HÁ, Hartley TF, et al. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women. Calcif Tissue Int. 1987;4: 7-10.
22. Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol. 1995;14:32-39.
23. Geusens P, Dequeker J, et al. Long term effect of nandrolone decanoate, 1 alfa hydroxivitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double blind controlled study. Bone Miner. 1986;1:347-357.
24. Flicker L, Hopper JL, Larkins RG, et al. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporosis Int. 1997;7:29-35.
25. World Health Organization (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: WHO; 1994. Technical report series no. 843.
26. Black DM, Palermo L, Nevitt MC, et al. for the Study of Osteoporotic Fractures Research Group. Defining incident vertebral deformity: a prospective comparison of several approaches. J Bone Miner Res. 1999;14:90-101.
27. Jerome CP, Power RA, Obasanjo IO, Register TC, Guidry M, Carlson CS, et al. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. Bone 1997;20:355-364.
28. Gadeleta SJ, Boskey AL, Paschalis E, Carlson C, Menschik F, Baldini T, et al. A physical, chemical, and mechanical study of lumbar vertebrae from normal, ovariectomized, and nandrolone decanoate-treated cynomolgus monkeys (Macaca fascicularis). Bone 2000;27:541-550.
29. Kanis JA, Beneton MNC, Gennari C, Gullberg B, Johnell O, Mazzuoli GF, et al. Effects of anabolic steroids on cortical bone and fractures. In: Christiansen C, Riis B, eds. Proceedings 1993; 4th International Symposium on Osteoporosis and Consensus Development Conference; Hong Kong, March 27-April 2, 1993. Aalborg, Handelstrykkeriet, 1993:308-310.
30. Hassanger C, Podenphant J, Riis BJ, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism. 1989; 38:238-242.
31. Shetty KR, Duthie EHJ, et al. Anterior pituitary function and growth hormone use in the elderly. Endocrinol Metab Clin North Am. 1995; 24:213-217.
32. Barret-Connor E, Goodman-Gruen D, et al. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. J Bone Miner Res. 1998;13: 1343-1349.
33. Hedstron M. Hip fracture subjects, a group of frail elderly people with low bone mineral density, muscle mass and IGF-1 levels. Review. Acta Physiol Scand. 1999;167:347-350.
34. Ravn P, Overgaard K, Spencer EM, Christiansen C. Insulin-like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol. 1995;132:313-319.
35. Hinterberger W, Vierhapper H, et al. Anabolic steroids and blood cell production. Wien Med Wochenschr. 1993;143:380-382.
36. Teruel JL, Marcén R, Navarro JF, et al. Evolution of serum erythropoietin after androgen administration to hemodialysis subjects: a prospective study. Nephron. 1995;70:282-286.
37. Cattran DC, Fenton SS, Wilson DR, et al. A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int. 1977;12:430-437.
38. Teruel JL, Aguilera A, Marcen R, et al. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Scand J Urol Nephrol. 1996;30:403-408.
39. Gennari C, Agnusdei D, Gonnelli S, et al. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double blind placebo controlled study. Maturitas. 1989;11:187-197.